PATH and partners are developing iOWH032 as a complement to oral rehydration solution for diarrheal disease treatment. Acting via inhibition of the cystic fibrosis transmembrane conductance regulator chloride channel, iOWH032 is a novel, low-molecular-weight compound intended to reduce fluid and electrolyte loss in cases of cholera toxin-induced secretory diarrhea.
Corporate author(s): PATH
Publication date: August 2017
628 KB PDF
Hard copies are not available.
Some digital files may be saved at low resolutions to conserve file size. Versions with higher quality may be available; see the contact information below to enquire.
Related regions: Global
- Emerging and epidemic diseases > Drug development
- Maternal and child health > Controlling diarrheal disease
For more information…
Contact: PATH Publications
Mailing address: PATH, PO Box 900922, Seattle, WA 98109 USA